Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.
M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.
Group revenue rises to EUR 237 million (EUR 82 million in Q3-2020)
Beauty: treatment numbers at high level; record revenue in German practice network in October 2021; no negative impact from rising incidence rate of the Corona pandemic
Group EBITDA amounts to EUR 13.3 million (previous year: EUR 8.8 million); EBIT amounts to EUR 9.1 million (previous year: EUR 5.8 million); EBIT margin in the German practice network in the target corridor of 15-20% despite large number of new openings
After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year and the future.
We use cookies on our website.Some of them are essential, while others help us to improve this website and your experience.
Technically necessary tools that enable essential services and basic functions, including identity verification, service continuity and site security. This option cannot be denied.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Speichert die aktuelle PHP-Session.
Third-party content, e.g. stock widgets, are blocked by default. If third-party cookies are accepted, access to this content no longer requires manual consent.
We use the TradingView to display stock charts. This provider uses additional cookies to analyze its services.
By using this website, you consent to the use of cookies. You can find detailed information on the use of cookies on this website in the data protection declaration.
Menu
